Date: Jan 06, 2016 Source: PR Newswire (
click here to go to the source)
SAN DIEGO, Jan. 6, 2016 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that leadership members will present at two high-profile investment conferences in January: Biotech Showcase 2016 and Noble Financial Capital Markets 12th Annual Investor Conference.
Biotech Showcase 2016
Punit Dhillon, President and CEO, and Robert H. Pierce, MD, Chief Scientific Officer, will present a corporate overview at the Biotech Showcase 2016 on Monday, January 11 at 11:00 AM PT on Track C -- Mission II (Fourth Floor) at Parc 55 San Francisco -- Union Square in San Francisco. Please visit the "Investors" section of OncoSec's website for webcast information: http://ir.oncosec.com/.
Biotech Showcase is an investor and networking conference devoted to providing biotechnology and life sciences companies with an opportunity to present and meet with investors and pharmaceutical executives during the course of one of the industry's largest annual healthcare investor conferences. In its eighth year, Biotech Showcase 2016 includes lunch plenary sessions featuring top industry leaders and innovators speaking on industry and time relevant topics, as well as presentations from both private and public companies. For more information, please visit: http://www.ebdgroup.com/bts/index.php.
Noble Financial Capital Markets 12th Annual Investor Conference
Mr. Dhillon will present a corporate overview at the Noble Financial Capital Markets 12th Annual Investor Conference on Tuesday, January 19 at 3:30 PM ET in Room 1 at Club Med Sandpiper Bay in Port St. Lucie, Florida.
The Noble Financial Capital Markets 12th Annual Investor Conference allows a diverse range of public and private companies to provide formal presentations and request face-to-face meetings with investors and corporate executives. The conference also stimulates dialogue with Noble analysts, investment bankers, and members of Noble's Scientific and Technology Advisory Boards during networking events after the completion of formal presentations. For more information, please visit: https://nobleconference.com/home.
About OncoSec Medical Incorporated
OncoSec is a biotechnology company developing DNA-based intratumoral immunotherapies with an investigational technology, ImmunoPulse™, for the treatment of cancer. ImmunoPulse™ is designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as IL-12. In Phase I and II clinical trials, ImmunoPulse™ IL-12 has demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various skin cancers as well as the potential to initiate a systemic immune response. OncoSec's lead program, ImmunoPulse™ IL-12, is currently in Phase II development for several indications, including metastatic melanoma, squamous cell carcinoma of the head and neck, and triple-negative breast cancer. In addition to ImmunoPulse™ IL-12, the Company is also identifying and developing new immune-targeting agents for use with the ImmunoPulse™ platform. For more information, please visit www.oncosec.com.
